Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Income (2023 - 2025)

Historic Net Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.

  • Monte Rosa Therapeutics' Net Income fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11751.67%. This contributed to the annual value of -$72.7 million for FY2024, which is 4626.6% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Net Income is -$27.1 million, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Net Income ranged from a high of $46.9 million in Q1 2025 and a low of -$35.2 million during Q2 2023
  • Its 3-year average for Net Income is -$18.2 million, with a median of -$30.3 million in 2024.
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' Net Income showed a top increase of 24658.43% in 2025 and a maximum decrease of 1350.43% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Net Income stood at -$33.3 million in 2023, then surged by 140.32% to $13.4 million in 2024, then tumbled by 301.99% to -$27.1 million in 2025.
  • Its last three reported values are -$27.1 million in Q3 2025, -$12.3 million for Q2 2025, and $46.9 million during Q1 2025.